Top-Rated StocksTop-RatedNASDAQ:ARVN Arvinas (ARVN) Stock Price, News & Analysis → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Free ARVN Stock Alerts $34.90 +0.18 (+0.52%) (As of 04/22/2024 ET) Add Compare Share Share Today's Range$34.52▼$35.8750-Day Range$33.44▼$52.3152-Week Range$13.57▼$53.08Volume848,716 shsAverage Volume726,713 shsMarket Capitalization$2.38 billionP/E RatioN/ADividend YieldN/APrice Target$59.73 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Arvinas alerts: Email Address Arvinas MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.88 Rating ScoreUpside/Downside71.2% Upside$59.73 Price TargetShort InterestBearish12.59% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.08Based on 5 Articles This WeekInsider TradingSelling Shares$404,489 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($5.02) to ($4.95) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.66 out of 5 starsMedical Sector416th out of 909 stocksPharmaceutical Preparations Industry186th out of 419 stocks 4.4 Analyst's Opinion Consensus RatingArvinas has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 14 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageArvinas has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 0.0 Short Interest Percentage of Shares Shorted12.59% of the outstanding shares of Arvinas have been sold short.Short Interest Ratio / Days to CoverArvinas has a short interest ratio ("days to cover") of 11.7, which indicates bearish sentiment.Change versus previous monthShort interest in Arvinas has recently increased by 8.59%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldArvinas does not currently pay a dividend.Dividend GrowthArvinas does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ARVN. Previous Next 2.8 News and Social Media Coverage News SentimentArvinas has a news sentiment score of 1.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Arvinas this week, compared to 3 articles on an average week.Search InterestOnly 1 people have searched for ARVN on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Arvinas to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Arvinas insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $404,489.00 in company stock.Percentage Held by InsidersOnly 5.23% of the stock of Arvinas is held by insiders.Percentage Held by Institutions95.19% of the stock of Arvinas is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Arvinas are expected to grow in the coming year, from ($5.02) to ($4.95) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arvinas is -5.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arvinas is -5.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArvinas has a P/B Ratio of 2.91. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaSHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. Claim your free seat by clicking here now. About Arvinas Stock (NASDAQ:ARVN)Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.Read More ARVN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ARVN Stock News HeadlinesApril 21, 2024 | americanbankingnews.comArvinas, Inc. (NASDAQ:ARVN) Given Average Rating of "Moderate Buy" by BrokeragesApril 20, 2024 | finance.yahoo.comArvinas, Inc. (ARVN)April 23, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. April 17, 2024 | americanbankingnews.comArvinas, Inc. (NASDAQ:ARVN) Short Interest Up 8.6% in MarchApril 14, 2024 | americanbankingnews.comArvinas (NASDAQ:ARVN) Price Target Lowered to $87.00 at HC WainwrightApril 13, 2024 | americanbankingnews.comArvinas (NASDAQ:ARVN) Shares Gap Up to $36.73April 11, 2024 | markets.businessinsider.comBuy Rating Affirmed for Arvinas Amid Strategic Novartis Deal and Growth PotentialApril 11, 2024 | investors.comBiotech Stocks Heat Up As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores OptionsApril 23, 2024 | Crypto 101 Media (Ad)SHOCKING Crypto Leak…A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024. April 11, 2024 | markets.businessinsider.comArvinas Enters Deal With Novartis For License Of ARV-766, Sale Of AR-V7 Program; Stock JumpsApril 11, 2024 | globenewswire.comArvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate CancerMarch 20, 2024 | seekingalpha.comArvinas gets new chief medical officerMarch 19, 2024 | msn.comArvinas gets new chief medical headMarch 18, 2024 | globenewswire.comArvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical OfficerMarch 4, 2024 | globenewswire.comArvinas to Participate in Upcoming Investor ConferencesMarch 3, 2024 | seekingalpha.comArvinas: Behind The Huge RallyMarch 1, 2024 | finance.yahoo.comArvinas, Inc. (NASDAQ:ARVN) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?February 28, 2024 | markets.businessinsider.comArvinas Holding Company: Buy Rating Backed by Promising Breast Cancer Therapy and Strategic Expansion into Parkinson’s Disease TreatmentFebruary 28, 2024 | markets.businessinsider.comPiper Sandler Keeps Their Buy Rating on Arvinas Holding Company (ARVN)February 28, 2024 | markets.businessinsider.comNavigating 7 Analyst Ratings For ArvinasFebruary 28, 2024 | markets.businessinsider.comBuy Rating Affirmed for Arvinas Holding Company Amid Strong Drug Candidate Prospects and Robust Financial HealthFebruary 27, 2024 | benzinga.comArvinas: Q4 Earnings InsightsFebruary 27, 2024 | globenewswire.comArvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate UpdateFebruary 24, 2024 | finance.yahoo.comArvinas (NASDAQ:ARVN) shareholders are still up 143% over 5 years despite pulling back 10% in the past weekFebruary 22, 2024 | marketwatch.comArvinas CFO Cassidy to Depart, Teel to Take Over on Interim BasisFebruary 21, 2024 | finance.yahoo.comWhat Makes Arvinas, Inc. (ARVN) a Strong Momentum Stock: Buy Now?February 21, 2024 | finanznachrichten.deArvinas Inc.: Arvinas Announces Chief Financial Officer TransitionSee More Headlines Receive ARVN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arvinas and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/27/2024Today4/22/2024Next Earnings (Estimated)5/03/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ARVN CUSIPN/A CIK1655759 Webwww.arvinas.com Phone(203) 535-1456FaxN/AEmployees445Year FoundedN/APrice Target and Rating Average Stock Price Target$59.73 High Stock Price Target$90.00 Low Stock Price Target$20.00 Potential Upside/Downside+71.2%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage16 Analysts Profitability EPS (Most Recent Fiscal Year)($6.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-367,300,000.00 Net Margins-185.09% Pretax Margin-463.57% Return on Equity-70.24% Return on Assets-31.79% Debt Debt-to-Equity RatioN/A Current Ratio4.98 Quick Ratio4.98 Sales & Book Value Annual Sales$78.50 million Price / Sales30.37 Cash FlowN/A Price / Cash FlowN/A Book Value$11.99 per share Price / Book2.91Miscellaneous Outstanding Shares68,310,000Free Float64,735,000Market Cap$2.38 billion OptionableOptionable Beta1.94 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesDr. John G. Houston Ph.D. (Age 64)Chairperson, CEO & President Comp: $1.08MDr. Ian Taylor Ph.D. (Age 61)Chief Scientific Officer Comp: $692kDr. Randy Teel Ph.D. (Age 44)Interim CFO & Treasurer Mr. David K. Loomis M.B.A. (Age 50)VP, Principal Accounting Officer & Chief Accounting Officer Mr. Jeff BoyleVice President of Investor RelationsMr. Jared M. Freedberg J.D. (Age 55)General Counsel & Corporate Secretary Mr. Steve Weiss (Age 54)Senior VP & Chief Human Resources Officer Dr. John A. Grosso Ph.D. (Age 67)Senior Vice President of R&D Technical Operations Ms. Angela M. Cacace Ph.D. (Age 56)Senior Vice President of Neuroscience & Platform Biology Mr. John P. Northcott (Age 46)Chief Commercial Officer More ExecutivesKey CompetitorsRhythm PharmaceuticalsNASDAQ:RYTMVera TherapeuticsNASDAQ:VERARocket PharmaceuticalsNASDAQ:RCKTMerusNASDAQ:MRUSTG TherapeuticsNASDAQ:TGTXView All CompetitorsInsiders & InstitutionsWasatch Advisors LPSold 15,516 shares on 4/18/2024Ownership: 0.305%Allspring Global Investments Holdings LLCBought 1,060 shares on 4/18/2024Ownership: 0.018%Cullinan Associates Inc.Bought 6,000 shares on 4/18/2024Ownership: 0.009%Hennion & Walsh Asset Management Inc.Bought 25,778 shares on 4/17/2024Ownership: 0.091%Los Angeles Capital Management LLCBought 1,993 shares on 4/5/2024Ownership: 0.044%View All Insider TransactionsView All Institutional Transactions ARVN Stock Analysis - Frequently Asked Questions Should I buy or sell Arvinas stock right now? 16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Arvinas in the last year. There are currently 2 hold ratings and 14 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ARVN shares. View ARVN analyst ratings or view top-rated stocks. What is Arvinas' stock price target for 2024? 16 Wall Street analysts have issued 12-month price targets for Arvinas' shares. Their ARVN share price targets range from $20.00 to $90.00. On average, they expect the company's share price to reach $59.73 in the next year. This suggests a possible upside of 71.2% from the stock's current price. View analysts price targets for ARVN or view top-rated stocks among Wall Street analysts. How have ARVN shares performed in 2024? Arvinas' stock was trading at $41.16 at the beginning of 2024. Since then, ARVN stock has decreased by 15.2% and is now trading at $34.90. View the best growth stocks for 2024 here. Are investors shorting Arvinas? Arvinas saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 8,600,000 shares, an increase of 8.6% from the March 15th total of 7,920,000 shares. Based on an average trading volume of 735,200 shares, the short-interest ratio is currently 11.7 days. View Arvinas' Short Interest. When is Arvinas' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 3rd 2024. View our ARVN earnings forecast. How were Arvinas' earnings last quarter? Arvinas, Inc. (NASDAQ:ARVN) released its quarterly earnings results on Tuesday, February, 27th. The company reported ($2.53) EPS for the quarter, missing the consensus estimate of ($1.15) by $1.38. The company had revenue of ($43.10) million for the quarter, compared to analysts' expectations of $38.91 million. Arvinas had a negative trailing twelve-month return on equity of 70.24% and a negative net margin of 185.09%. During the same quarter in the previous year, the firm posted ($1.56) EPS. What ETFs hold Arvinas' stock? ETFs with the largest weight of Arvinas (NASDAQ:ARVN) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH), Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL), ALPS Medical Breakthroughs ETF (SBIO), Tema Oncology ETF (CANC), iShares U.S. Pharmaceuticals ETF (IHE), Zacks Small/Mid Cap Core Portfolio ETF (SMIZ) and Harbor Disruptive Innovation ETF (INNO).First Trust Nasdaq Pharmaceuticals ETF (FTXH). What other stocks do shareholders of Arvinas own? Based on aggregate information from My MarketBeat watchlists, some companies that other Arvinas investors own include Dynavax Technologies (DVAX), ImmunoGen (IMGN), Pfizer (PFE), CRISPR Therapeutics (CRSP), Energy Transfer (ET), OPKO Health (OPK), Advanced Micro Devices (AMD), Enphase Energy (ENPH), Fortress Biotech (FBIO) and Gilead Sciences (GILD). When did Arvinas IPO? Arvinas (ARVN) raised $100 million in an initial public offering (IPO) on Thursday, September 27th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray served as the underwriters for the IPO. Who are Arvinas' major shareholders? Arvinas' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Wasatch Advisors LP (0.30%), Hennion & Walsh Asset Management Inc. (0.09%), Los Angeles Capital Management LLC (0.04%), Allspring Global Investments Holdings LLC (0.02%) and Cullinan Associates Inc. (0.01%). Insiders that own company stock include Bradley Albert Margus, Briggs Morrison, Ian Taylor, John G Houston, John G Houston, Liam Ratcliffe, Ronald Peck, Sean A Cassidy and Timothy M Shannon. View institutional ownership trends. How do I buy shares of Arvinas? Shares of ARVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ARVN) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingHealthcare Takes A Big Step Forward With The Help Of AIThe Bull Reporttop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap Profits[Shocking] Elon Musk’s Plan To End BanksCrypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThe #1 Crypto for 2024InvestorPlaceMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arvinas, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
